Upadacitinib for relapsing polychondritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have relapsing polychondritis that meets official diagnostic criteria.
- Your disease is still active despite at least 4 weeks of standard treatment (such as prednisone up to 0.5 mg/kg or certain immune-suppressing drugs).
- You have not used rituximab or similar antibody therapies in the past 2 months.
- You do not have a serious infection, active tuberculosis, HIV, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to treating relapsing polychondritis, a rare autoimmune condition that causes inflammation in cartilage like the ears, nose, and airways. It aims to see if a more tailored treatment can help control symptoms while reducing prednisone use.
This study follows people who have been diagnosed with relapsing polychondritis over time. It aims to better understand the condition and how it progresses, which may help future care.
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
This study tests whether a higher dose of upadacitinib (45 mg) can help people with ulcerative colitis whose symptoms come back while on the usual 30 mg maintenance dose. If you've lost response to your current treatment, this re-induction approach may help you get back into remission.
Hear when a new Relapsing Polychondritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.